Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Bristol-Myers, Pfizer Prepare Launch of Clot-Buster

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/24/2013 | 09:25pm CEST

--Eliquis seen generating multibillion-dollar annual sales

--Drug approved in December by FDA to reduce risk of stroke in people with irregular heartbeat

--Eliquis to enter competitive market against other new anticlotting drugs

(Adds comment from Boehringer Ingelheim spokeswoman in 13th paragraph.)

 
   By Peter Loftus 
 

Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) and Pfizer Inc. (>> Pfizer Inc.) plan to launch the anticlotting drug Eliquis in the U.S. next week, kicking off a marketing campaign that could eventually generate billions of dollars in sales.

The U.S. Food and Drug Administration approved Eliquis in late December to be used to reduce the risk of stroke and certain blood clots in people with an irregular heartbeat known as atrial fibrillation. Some analysts think the drug's annual sales could eventually top $4 billion.

Eliquis is one of a new crop of blood thinners known as anticoagulants that aim to replace--in some medical situations--an older drug, warfarin, which has been the standard of care for decades but which can be cumbersome to administer. Eliquis will compete with Xarelto, co-marketed by Johnson & Johnson (>> Johnson & Johnson) and Bayer AG (BAYN.XE, BAYRY), as well as Pradaxa from Boehringer Ingelheim GmbH, both of which are already on the market.

Bristol-Myers and Pfizer plan to launch Eliquis in the U.S. next week, and the companies are making similar plans in other countries, Bristol-Myers Chief Executive Lamberto Andreotti said on a conference call with analysts Thursday morning.

"Our teams have been working together, planning for this day, preparing for our launch," he said. The companies initially hoped to begin selling Eliquis in the U.S. last year, but the FDA extended its review after asking for more information about the drug.

Bristol-Myers spokeswoman Laura Hortas said the drug has already been shipped and is expected to be available in pharmacies soon, with full promotional activities beginning in early February. The drug has a wholesale acquisition cost of $8.35 per day.

The companies are working with health insurers and payers to secure reimbursement and patient access to the drug, said Giovanni Caforio, president of Bristol-Myers' U.S. pharmaceuticals unit. The companies also are planning a program to assist with out-of-pocket costs for the drug, he said.

Pfizer and Bristol-Myers believe Eliquis will have an edge over competing drugs because it demonstrated superiority versus warfarin in clinical trials in reducing risk of three key outcomes: stroke and systemic embolism, major bleeding and all-cause mortality.

"This unique and differentiated profile of Eliquis will resonate and will position us well against warfarin and against all other anticoagulants," Mr. Andreotti said.

Analysts have said the relatively strong clinical data for Eliquis could eventually make it the preferred choice among doctors. But a challenge for Pfizer and Bristol-Myers is to overcome "third-to-market status and general market inertia with warfarin," Leerink Swann analyst Seamus Fernandez said in a recent note. This could make for slow sales early on, picking up over time, he said.

The prescribing label for Eliquis also carries a prominent warning that discontinuing the drug could increase risk of clots and strokes, as does Xarelto's label.

William Foster, spokesman for J&J's Janssen unit, said Xarelto has the broadest profile of any of the new oral anticoagulants on the U.S. market, with six distinct uses approved by FDA. He said more than one million Xarelto prescriptions were written last year.

Boehringer Ingelheim spokeswoman Mary Lewis said Pradaxa reduced the risk of ischemic stroke and hemorrhagic stroke versus warfarin in atrial-fibrillation patients in clinical testing. "We are confident that Pradaxa will continue to be a dominant player" in the market for oral anticoagulants, she said.

Bristol-Myers discovered Eliquis and formed a partnership with Pfizer in 2007 to co-develop and co-commercialize the drug. The companies share commercialization expenses and profits equally on a global basis. The drug's U.S. patent is due to expire in 2023, according to a Bristol-Myers regulatory filing.

Write to Peter Loftus at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bristol Myers Squibb Co., Pfizer Inc., Johnson & Johnson
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB CO
04/22 BRISTOL MYERS SQUIBB : BMS-986036 (Pegylated FGF21) Shows Consistent Improvement..
04/21 BRISTOL MYERS SQUIBB : Receives Positive CHMP Opinion Recommending Approval of O..
04/20 BRISTOL MYERS SQUIBB : Trademark Application for "SUPPORT AT THE SPEED OF LIFE" ..
04/20 BRISTOL MYERS SQUIBB : and Apexigen, Inc. Announce Clinical Collaboration to Eva..
04/20 BRISTOL MYERS SQUIBB : Bavarian Nordic Announces Initiation of Phase 2 Combinati..
04/18 BRISTOL MYERS SQUIBB : Myers, Nordic Bioscience To Develop Fibrosis Biomarker Te..
04/18 BRISTOL-MYERS SQUIBB CO : Blog Coverage Bristol-Myers and Nordic Announce an Agr..
04/17 BRISTOL-MYERS SQUIBB : and Nordic Bioscience Announce Collaboration for Fibrosis..
04/15 BRISTOL MYERS SQUIBB : Myers offloads anti-tau, DMD assets to Biogen, Roche for ..
04/14 Roche, Biogen handing over $470M in cash to bag two drug programs from Bristo..
More news
Sector news : Pharmaceuticals - NEC
03:01a Becton Dickinson to acquire Bard for $24 billion
04/22DJNOVARTIS : Tests New Alzheimer's Drug on People Who Don't Have the Disease
04/21DJFDA OKs Samsung Bioepis's biosimilar version of J&J's Remicade
04/21 Teva's new asthma inhaler poses first competition for GSK's Advair
04/19DJSHIRE : Files 8K - Other Events
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/22 3 THINGS IN BIOTECH YOU SHOULD LEARN : April 22, 2017
04/21 Bristol's Search For Yervoy Mark II
04/21 EMA hands down a number of recommendations
04/21 Merck Leads Rivals In Novel Drug Approvals
04/20 Medidata To Acquire Mytrus For Patient eConsent System
Advertisement
Financials ($)
Sales 2017 19 736 M
EBIT 2017 5 195 M
Net income 2017 4 482 M
Finance 2017 393 M
Yield 2017 3,05%
P/E ratio 2017 19,90
P/E ratio 2018 18,16
EV / Sales 2017 4,44x
EV / Sales 2018 4,26x
Capitalization 88 108 M
More Financials
Chart BRISTOL-MYERS SQUIBB CO
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 55,8 $
Spread / Average Target 4,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..-8.49%88 108
JOHNSON & JOHNSON5.69%330 078
ROCHE HOLDING LTD.8.21%217 624
PFIZER INC.3.57%200 330
NOVARTIS AG-1.08%192 857
MERCK & CO., INC.5.13%169 673
More Results